CC
SPRY icon

Clearline Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Clearline Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-271,678
Closed -$1.03M – 126
2023
Q3 		$1.03M Buy
271,678
+210,576
+345% +$1.38M 0.09% 100
2023
Q2 		$409K Buy
+61,102
New +$408K 0.02% 103

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Clearline Capital's SPRY Position: Q4 2023 in Review

Clearline Capital sold out of ARS Pharmaceuticals (SPRY) in Q4 2023, closing a stake of 271,678 shares — an estimated $1.03M sold.

Clearline Capital first reported a position in SPRY in Q2 2023 and held it in 2 quarters. The position peaked at $1.03M in Q3 2023. 100 funds tracked by Wall St. Rank hold SPRY as of Q4 2023.

  • Clearline Capital reported no remaining ARS Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Clearline Capital sold 271,678 ARS Pharmaceuticals shares in Q4 2023, an estimated $1.03M.
  • Clearline Capital first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Clearline Capital's ARS Pharmaceuticals position peaked at $1.03M in Q3 2023.
  • 100 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2023.

Based on Clearline Capital's 13F filing for Q4 2023, filed 14 Feb 2024.